Switching to fingolimod in MS therapy – risk or benefits? Case reports Case report

Abstract

Approving of disease modifying drugs (DMD) in clinical practice was the breakthrough in the multiple sclerosis therapy. Until now, only interferon beta and glatiramer were used as safe drugs but with limited therapeutic efficacy. Most of validated data suggested that the treatment of multiple sclerosis should be started very early to slow the progression of disease and disability. Approving of new drugs – fingolimod and natalizumab – and the possibility of their reimbursement in Poland are connected with superior benefits in MS therapy. To get the best efficacy and safety of the treatment with new drugs, the inclusion criteria to the therapy and monitoring of adverse events must be performed. Two described cases concern the switching of MS therapy and outcome benefits.